Jefferies 2012 Global Healthcare Conference 2012 Global Healthcare Conference This presentation includes forward-looking statements. Actual results could differ materially from those

June 8, 2012

Jefferies 2012 Global Healthcare Conference

This presentation includes forward-looking statements.

Actual results could differ materially from those included in the forward-looking statements

due to various risk factors and uncertainties including changes in business, economic

competitive conditions, regulatory reforms, foreign exchange rate fluctuations and the

availability of financing.

These and other risks and uncertainties are detailed in the Company’s Annual Report.

Safe Harbour

© MorphoSys AG © MorphoSys AG

Components of the Business

Page 3

Innovative Product Pipeline Technology-driven Alliances

AbD Serotec Financially Strong

MOR103 phase 1b/2a data

coming soon

Four partner phase 2 studies

complete in 2012

20 clinical programs

Proven HuCAL platform

Novel Slonomics and

Ylanthia technologies

provide new opportunities

Emerging diagnostics

business

Research antibody catalog

Sustainably cash-flow positive

Strong balance sheet

Company Update - June 2012


Technology-driven Alliances

Company Update - June 2012 Page 4


Proprietary Technology Platform Underpins

Lucrative Alliances

MorphoSys has successfully partnered its human antibody technology HuCAL with many of the

leading pharmaceutical companies

Lucrative model

Makes MOR cash-flow positive

Funds proprietary R&D

Future upside from milestones & royalties

Page 5

MorphoSys Pharma partner

Target

HuCAL antibody drug

candidate

R&D funding

Technology licence fees

Milestones and royalties



Case Study: MorphoSys-Novartis

One of the largest discovery alliances in the industry

Term Through 2017, subject to 2-year extension option

Novartis pays…

Approx. €20m p.a. technology license fees

Approx. €20m p.a. in research funding

Milestones and royalties on all resulting drugs

Novartis gets… Preferred access to HuCAL for use in over 100

discovery programs

Co-development

option

Shared costs & profits (20% – 50%) on selected co-

developed programs

Excluded Most infectious disease targets

Page 6 Company Update - June 2012


New Technologies Drive New Deals

Page 7

Slonomics

Best technology for making protein libraries

Exclusive access secured through acquisition

of Sloning Biotechnology in 2010

Deals have already paid for acquisition

Pfizer

Novozymes

Unnamed pharma

Ylanthia

Totally new antibody platform

Higher quality antibodies, greater diversity,

better biophysical properties, faster lead

generation

Opens new opportunities



Innovative Product Pipeline



20 Therapeutic Antibody Programs

in Clinical Trials

Page 9

Program Partner Target Indication Discovery Pre-clinic Phase 1 Phase 2 Phase 3

Gantenerumab Roche Amyloid-ß Alzheimer’s Disease

MOR103

(2 programs) - GM-CSF

Rheumatoid Arthritis

Multiple sclerosis

CNTO888 Janssen/J&J MCP-1 (CCL-2) IPF

CNTO1959 Janssen/J&J IL23p19 Psoriasis

BHQ880 Novartis DKK-1 Cancer

BYM338 Novartis - Musculoskeletal

NOV – 3 Novartis - not discl.

NOV – 4 Novartis - Ophthalmology

MOR208 - CD19 CLL

MOR202 - CD38 MM

BAY94-9343 Bayer Healthcare Mesothelin (ADC) Cancer

BI – 1 BI - not discl.

CNTO3157 Janssen/J&J - Asthma

CNTO – 5 Janssen/J&J - Inflammation

NOV – 5 Novartis - Inflammation

NOV – 6 Novartis - Cancer

OMP-18R5 Oncomed Fzd 7 Cancer

OMP-59R5 Oncomed Notch 2/3 Cancer

PFE – 1 Pfizer - Cancer

19 Partnered

Programs Various Partners - Various Indications

32 Programs, incl.

2 co-dev with NOV Various Partners - Various Indications

63 Partnered Programs

8 Proprietary Programs



Partner Program Case Study

Gantenerumab: Alzheimer’s Disease

The Drug

High affinity HuCAL antibody targeting amyloid-b

Binds N-terminus and mid-section of Ab40-42 peptide

Large Market and Unmet Need

AD is estimated to affect 25 million people worldwide

High unmet medical need, no curative treatments available

Clinical Development

Phase 1, in patients: Completed

Gantenerumab: Rapid, dose-dependent reduction of

plaque: 16-36% reduction within 7 months

Bapineuzumab: 9% plaque reduction over 18 months

Phase 2: Pivotal Phase 2/3 Study Ongoing

770 prodromal patients, 2 doses, placebo-controlled

104 weeks on drug

CDR-SOB, ADAS-COG, change in brain amyloid

Favorable outcome to the trial could be used by Roche to

support a marketing application



MOR103

A Novel Anti-Inflammatory Antibody

The Drug

Ultra-high affinity HuCAL IgG1 targeting GM-CSF

GM-CSF is a key inflammatory mediator in rheumatoid arthritis and other

inflammatory conditions

Potential to become first and best-in-class anti-GM-CSF mAb


Revenues with approved biologics in rheumatoid arthritis over $12bn

50% of RA patients do not respond to anti-TNF therapy beyond 2 years

Potential in MS, osteoarthritis, pain, asthma, COPD

Intellectual Property

Exclusive license to a US patent covering anti-GM-CSF antibodies for the

treatment of chronic inflammatory conditions

US patent on MOR103 composition of matter



MOR103 is A Novel Drug in a Clinically

Validated Pathway

Clinical Validation of Pathway

Phase 2 data for mavrilimumab, antibody vs.

GM-CSF receptor, provides clinical

validation of the pathway in rheumatoid

arthritis

Clinical Development of MOR103

Phase 1, in healthy volunteers: MOR103

generally safe and well-tolerated

Phase 1b/2a, in RA patients: Fully recruited,

data expected in Q3 2012

Phase 1, PK study for sc administration:

Initiated Q1 2012, data expected in Q3 2012

Phase1b, safety study in MS patients:

Initiated Q4 2011, data expected in 2013

Proportion of subjects achieving a change of 1.2 from

baseline in DAS28-CRP

Source: ACR2011 Abstract: Mavrilimumab (an Anti-GM-CSFRα

Monoclonal Antibody) in Subjects with Rheumatoid Arthritis:

Results of a Phase 2 Randomized, Double-Blind, Placebo-

Controlled Study

http://acr.confex.com/acr/2011/webprogram/Paper24567.html

Phase 2 data for mavrilimumab


http://acr.confex.com/acr/2011/webprogram/Paper24567.html


MOR103

Clinical Trials in RA and MS

Rheumatoid arthritis Multiple sclerosis

Patients Patients with active rheumatoid arthritis Patients with relapsing-remitting or secondary progressive multiple sclerosis

Study Design

Randomized, double-blind, vs. stable regimen of RA therapy (NSAIDs, steroids, non- biological DMARDs)

0.3/1.0/1.5 mg/kg MOR103

Randomized, double-blind, placebo-controlled

0.5/1.0/2.0 mg/kg MOR103

Primary Endpoint

Adverse event rate and safety profile Incidence and severity of adverse events

Secondary Endpoints

DAS28, ACR core set measures and EULAR28 response criteria, hematology, blood chemistry, Ig levels, cytokines, synovitis, bone edema

Pharmacokinetic profile

Potential immunogenicity

Study Details

96 patients

Inclusion of MRI to detect an effect on inflammatory changes such as synovitis or bone edema

30 patients



MOR208 (XmAb5574)

A Novel Anti-Cancer Antibody

The Drug

Humanized, high affinity anti-CD19 antibody

Exclusive license from Xencor

Antibody comprises a proprietary Xencor modification of the Fc

part of the antibody leading to rapid and sustained B-cell

depletion


High unmet medical need in NHL, CLL & ALL

Revenues with approved drugs in B cell malignancies (CLL,

NHL & ALL) exceed $5bn

Relapsing patients have only limited treatment options

In ALL no antibody therapy at all exists and current

chemotherapy regimens are associated with very unfavorable

safety profile



MOR208 (XmAb5574)

A Novel Anti-Cancer Antibody

Clinical Validation of Pathway

Phase 2 data for blinatumomab validate CD19 as target for B-cell

malignancies

MOR208 Has An Attractive Competitive Profile

Expect convenient dosing schedule

Straightforward manufacturing

Potential for good safety profile

Significantly increased ADCC compared to unmodified antibody


Phase 1, in 30 relapsed or refractory CLL/SLL patients:

Recruitment nearly completed

Data expected in H2 2012

Phase 2: Trials in B cell malignancies starting Q4 2012



MOR202 – A Novel High-Potential Antibody

for Multiple Myeloma

The Drug

High affinity HuCAL antibody targeting CD38


Revenues with approved drugs in MM exceed $2bn

MM median survival is approximately 3-5 years

Competitive Profile

Pre-clinical data show strong synergy in combinations of

MOR202 with Velcade or Revlimid


Phase 1, in relapsed or refractory MM patients: ongoing

Phase 2a, monotherapy extension

Phase 1b, MOR202 + Velcade

Phase 1b, MOR202 + Revlimid

Up to 82 patients, at sites in Germany and Austria

Page 16

Non-inocula

ted

Vehicle

MOR202 3

mg/k

g

0.6m

g/kg B

OR

MOR202+BOR (3

+0.6m

g/kg)

0102030405060708090

100110

% l

ys

is o

f v

eh

icle

co

ntr

ol

MO

R2

02

/ V

elc

ad

e

Graft-induced bone lysis model of

multiple myeloma in mouse

Non-inocula

ted

Vehicle

MOR202 3

mg/k

g

LEN 50m

g/kg

MOR202+LEN (3

+50mg/k

g)

0102030405060708090

100110

% ly

sis

of

ve

hic

le c

on

tro

l

MO

R2

02

/ R

evli

mid



AbD Serotec



AbD Serotec Segment Complements

Therapeutic Business

Page 18

Research Activities

Catalogue of 15,000+ products

Stable and recurring cash flows

Customers comprise universities, government bodies, life science companies

Website, eCommerce

HuCAL – Diagnostic Applications

Custom antibody generation

Using proprietary technologies to deliver superior Dx antibodies

Future upside via royalties

Working with over 20 Dx companies



Strong Financials



Key Financials

in € million 2011 Guidance 2012 Q1 2012

Group Revenues 100.8 75 – 80 16.1

Total Operating Expenses 89.1 17.0

COGS 7.0 1.7

Funded R&D 20.7 4.0

Proprietary R&D (incl. technology development) 36.8 20 – 25 6.4

Sales, General & Administrative Expenses 24.6 4.9

EBIT 10.1 1 – 5 (0.8)

Cash & Marketable Securities (at end of period) 134.4 137.4



Shareholdings


Shares issued: 23,154,806 (March 31, 2012)

Treasury stock: 163,915 (March 31, 2012)

797,502 stock options and 328,050 convertible bonds outstanding (4.6%; December 31, 2011)


Milestones in 2012

Proprietary Portfolio

MOR103 Phase 1b/2a data in RA

MOR208

Phase 1 data in CLL

Pre-clinical data to be presented at ASCO

MOR202 to continue enrollment in phase 1 trial in MM patients

Partnered Pipeline

Several phase 2 studies will complete in 2012*

CNTO888 (Janssen Biotech, IPF)

BHQ880 (Novartis, oncology)

BYM338 (Novartis, musculoskeletal diseases)

Novartis (n.d.)

1-3 new INDs

Technology-driven alliances

New diagnostic products from AbD Serotec


* MorphoSys estimates based on publicly-available information

www.morphosys.com

Thank You

HuCAL®, HuCAL GOLD®, HuCAL PLATINUM®, Ylanthia®, arYla®, CysDisplay®, RapMAT® and AutoCAL® are registered trademarks of MorphoSys AG.

Slonomics® is a registered trademark of Sloning BioTechnology GmbH, a subsidiary of MorphoSys AG.

Dr. Claudia Gutjahr-Löser

Head of Corporate Communications & IR

Phone +49 (0)89 / 899 27-122

Fax +49 (0)89 / 899 27-5122

Email [email protected]

Dr. Simon Moroney

Chief Executive Officer

Phone +49 (0)89 / 899 27-311

Fax +49 (0)89 / 899 27-5311

Documents

Jefferies 2012 Global Healthcare Conference 2012 Global Healthcare Conference This presentation includes forward-looking statements. Actual results could differ materially from those